The dataset ranks 100 assignees by patent family count, and the leading assignee holds 149 records against 51 at fifth place and 36 at tenth place. That is a steep drop after the top few names, meaning leadership is real but not a monopoly — the top 10 together hold 55.2% of all 1,244 records in scope, leaving nearly half the field spread across the remaining 90 ranked companies. Anyone assessing competitive risk should look at the specific claim scope of the top handful rather than assume a single dominant player controls the space.

Filing volume peaked in 2021 at 86 records and had fallen to 23 by 2024, a 73% decline over that three-year span — the last period the trend can be read as complete. Because publication typically lags actual filing by around 18 months, 2025 and 2026 figures are still incomplete and should not be read as confirming a continued fall. The honest read is that the field has cooled from its early-2020s peak, with the true current trajectory not yet fully visible in the published data.

Implant and prosthesis claims (IPC class A61F) appear on 66.4% of the 1,244 records in scope, ahead of surgery and diagnosis claims (A61B) at 53.8% and body-fluid device claims (A61M) at 50.6%. These three classes cover the core mechanics of filter and deflection devices and their delivery systems. Smaller classes covering welding/soldering, braiding, electrotherapy, perforation and healthcare informatics each sit at or below 3.3% of records, marking those as comparatively under-claimed branches.